Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To better understand the physiologic excretion and/or catabolism of circulating peripheral amyloid beta (Abeta), we labeled human Abeta40 (monomeric, with predominant unordered structure) and Abeta42 (mixture of monomers and oligomers in approximately 50:50 ratio, rich in beta-sheet conformation) with either Na(125)I or (125)I-tyramine cellobiose, also known as the cell-trapping ligand procedure, testing their blood clearance and organ uptake in B6SJLF1/J mice. Irrespective of the labeling protocol, the peptide conformation, and the degree of oligomerization, both Abeta40 and Abeta42 showed a short half-life of 2.5-3.0 min. The liver was the major organ responsible for plasma clearance, accounting for >60% of the peptide uptake, followed by the kidney. In vivo, hepatocytes captured >90% of the radiolabeled peptides which, after endocytosis, were preferentially catabolized and excreted into the bile. Biliary excretion of intact as well as partially degraded Abeta species became obviously relevant at doses above 10 microg. The use of biotin-labeled Abeta allowed the visualization of the interaction with HepG2 cells in culture, whereas competitive inhibition experiments with unlabeled Abeta demonstrated the specificity of the binding. The capability of the liver to uptake, catabolize, and excrete large doses of Abeta, several orders of magnitude above its physiologic concentration, may explain not only the femtomolar plasma levels of Abeta but the little fluctuation observed with age and disease stages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid degradation of Aβ in the periphery (t1/2 = 2–3 min) precludes a direct and sensitive measurement of the rate of Aβ appearance from brain into blood (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The rapid degradation of Aβ once it enters the blood from brain precludes direct and reliable measurement of its influx rate by conventional means (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The liver clears approximately 60% of circulating Aβ.226”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [226]
Citations
Cites
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Self-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationTargeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Basic and Clinical Pharmacology
Wingard, L. B. (1983) · Anesthesia & Analgesia · doi:10.1213/00000539-198308000-00015 · Cited by 630
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Research works printed but not linked: 5
- Seglen, 1993, Methods Toxicol., 1, 231
- Friedman, 1993, Methods Toxicol., 1, 292
- Baltz, 1985, Clin. Exp. Immunol., 59, 235
- Authier, 1996, Clin. Investig. Med., 19, 149
- Hone, 2003, J. Alz. Dis., 5, 1
Cited by
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W. M., Patton, R. L., Luehrs, D. C., Daugs, I. D., Kuo, Y., et al. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.10.004 · Cited by 414
Craft, S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.021 · Cited by 348
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., Lacombe, D., Kong, X., Aman, A., Laurin, J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 307
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, T. F., Currie, J., Chan, S. G., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.008 · Cited by 292
Xiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Clearance of Amyloid Beta and Tau in Alzheimer’s Disease: from Mechanisms to Therapy
Xin, S.-H., Tan, L., Cao, X., Yu, J.-T., & Tan, L. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9895-1 · Cited by 210
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
Aisen, P. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 201
Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201
Self-citationMa, M., Liu, Z., Gao, N., Pi, Z., Du, X., Ren, J., & Qu, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c08395 · Cited by 187
Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175
Plasma biomarkers for mild cognitive impairment and Alzheimer's disease
Song, F., Poljak, A., Smythe, G. A., & Sachdev, P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.003 · Cited by 173
“Peripheral Aβ is uptaken and degraded in the liver, and excreted through the kidneys (Ghiso et al., 2004).”
BackgroundTargeting amyloid clearance in Alzheimer's disease as a therapeutic strategy
Nalivaeva, N. N., & Turner, A. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14593 · Cited by 172
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., & Kosenko, E. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.005 · Cited by 165
“Mass spectrometry analysis of the Aβ species in bile following single intravenous injection of mice with Aβ1–40 or Aβ1–42 identified a number of fragments in the bile; however, Aβ25–35 was not found in a variety of tissues (Ghiso et al., 2004).”
BackgroundCastellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154
Erickson, M. A., Hartvigson, P. E., Morofuji, Y., Owen, J. B., Butterfield, D. A., & Banks, W. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-150 · Cited by 145
In silico approaches for predicting the half-life of natural and modified peptides in blood
Mathur, D. D., Singh, S., Mehta, A., Agrawal, P., & Raghava, G. P. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196829 · Cited by 138
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Toledo, J. B., Shaw, L. M. J., & Trojanowski, J. Q. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt162 · Cited by 149
The role of amyloid-beta in the regulation of memory
Morley, J. E., & Farr, S. A. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.018 · Cited by 164
Burgess, B. L., McIsaac, S. A., Naus, K. E., Chan, J. Y., Tansley, G. H. K., Yang, J., Miao, F., Ross, C. J. D., van Eck, M., & Hayden, M. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.007 · Cited by 115
Is Alzheimer’s Disease a Liver Disease of the Brain?
Bassendine, M. F., Taylor-Robinson, S. D., Fertleman, M., Khan, M., & Neely, D. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190848 · Cited by 124
Blasko, I., Jellinger, K. A., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Tragl, K. H., & Fischer, P. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.002 · Cited by 130
Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
APP/Aβ structural diversity and Alzheimer's disease pathogenesis
Roher, A. E., Kokjohn, T. A., Clarke, S. G., Sierks, M. R., Maarouf, C. L., Serrano, G. E., Sabbagh, M., & Beach, T. G. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.007 · Cited by 133
“Under normal circumstances Ab is proteolytically degraded in brain or cleared by the liver and kidneys (Ghiso et al., 2004; Miners et al., 2008; Saito and Ihara, 2014), but very little is known about the catabolism of the PTM Ab peptides.”
Hemming, M. L., Selkoe, D. J., & Farris, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.004 · Cited by 128
“…of significant ACE inhibition to modulate Aβ levels in the periphery may be due to the vast majority of peripheral Aβ being degraded by the liver (Ghiso et al., 2004), which notably does not express ACE or several other Aβ-degrading proteases, including neprilysin, that are important for Aβ…”
BackgroundInsights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 116
Amyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
“For example, higher molecular mass AβOs can be characterized by size-exclusion high performance liquid chromatography (SEC-HPLC) or atomic force/electron microscopy (Ghiso et al., 2004; Stine, Dahlgren, Krafft, & LaDu, 2003).”
Tamaki, C., Ohtsuki, S., & Terasaki, T. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.036913 · Cited by 111
“This rapid clearance of plasma A (1–40) is largely mediated by the liver (Hone et al., 2003; Ghiso et al., 2004), and low-density lipoprotein receptor-related protein (LRP-1) is the major receptor responsible for the hepatic A (1–40) uptake (Tamaki et al., 2006).”
BackgroundInfluentialPorphyromonas gingivalis Infection Induces Amyloid-β Accumulation in Monocytes/Macrophages
Nie, R., Wu, Z., Ni, J., Zeng, F., Yu, W., Zhang, Y., Kadowaki, T., Kashiwazaki, H., Teeling, J. L., & Zhou, Y. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190298 · Cited by 108
Ito, S., Ohtsuki, S., & Terasaki, T. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.07.006 · Cited by 99
Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02559-z · Cited by 110
Nishida, Y., Ito, S., Ohtsuki, S., Yamamoto, N., Takahashi, T., Iwata, N., Jishage, K.-I., Yamada, H., Sasaguri, H., Yokota, S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054056 · Cited by 113
Guo, Y.-X., He, L., Zhang, M., Wang, F., Liu, F., & Peng, W. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.041 · Cited by 103
Amyloid-β Induces Hepatic Insulin Resistance by Activating JAK2/STAT3/SOCS-1 Signaling Pathway
Zhang, Y., Zhou, B., Zhang, F., Wu, J., Hu, Y., Liu, Y., & Zhai, Q. (2012) · Diabetes · doi:10.2337/db11-0499 · Cited by 92
Amyloid β Levels in Human Red Blood Cells
Kiko, T., Nakagawa, K., Satoh, A., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049620 · Cited by 106
Zhu, X., Yu, J., Jiang, T., Wang, P., Cao, L., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8723-8 · Cited by 94
Bertram, S., Brixius, K., & Brinkmann, C. K. (2016) · Endocrine · doi:10.1007/s12020-016-0976-8 · Cited by 94
Fanlo-Ucar, H., Picón-Pagès, P., Herrera-Fernández, V., ILL‐Raga, G., & Muñoz, F. J. (2024) · Antioxidants · doi:10.3390/antiox13101208 · Cited by 101
Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease
Kulstad, J. J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Rhoads, K., Mehta, P. D., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000216274.58185.09 · Cited by 92
Amyloid-β Induces Hepatic Insulin Resistance In Vivo via JAK2
Zhang, Y., Zhou, B. Z., Deng, B., Zhang, F., Wu, J., Wang, Y., Le, Y., & Zhai, Q. (2012) · Diabetes · doi:10.2337/db12-0670 · Cited by 93
Peripheral Amyloid-β Levels Regulate Amyloid-β Clearance from the Central Nervous System
Marques, M. A., Kulstad, J. J., Savard, C. E., Green, P. S., Lee, S. P., Craft, S., Watson, G. S., & Cook, D. G. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0964 · Cited by 81
Alzheimer culprits: Cellular crossroads and interplay
Claeysen, S., Cochet, M., Donneger, R., Dumuis, A., Bockaert, J., & Giannoni, P. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.05.008 · Cited by 96
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
“They show a high tendency for aggregation, and adopt a range of assembled states (monomers, dimers, oligomers, protofibrils, and fibrils) that ultimately leads to plaque formation (Ghiso et al., 2004b; Tarasoff-Conway et al., 2015).”
BackgroundInfluentialPlatelet β-secretase activity is increased in Alzheimer's disease
Johnston, J. A., Liu, W. W., Coulson, D. T. R., Todd, S., Murphy, S., Brennan, S., Foy, C. J., Craig, D., Irvine, G. B., & Passmore, A. P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.003 · Cited by 84
Impaired hepatic amyloid-beta degradation in Alzheimer’s disease
Maarouf, C. L., Walker, J. E., Sue, L. I., Dugger, B. N., Beach, T. G., & Serrano, G. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203659 · Cited by 77
Morales‐Corraliza, J., Wong, H., Mazzella, M. J., Che, S., Lee, S. H., Petkova, E., Wagner, J. D., Hemby, S. E., Ginsberg, S. D., & Mathews, P. M. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4640-14.2016 · Cited by 83
“Unlike in the periphery, in which A is cleared rapidly by the liver and also excreted into the urine (Ghiso et al., 2004), cerebral A clearance is dependent on local degradation and transport across the BBB.”
BackgroundTauroursodeoxycholic acid prevents E22Q Alzheimer’s Aβ toxicity in human cerebral endothelial cells
Viana, R. J. S., Nunes, A. F., Castro, R. E., Ramalho, R. M., Meyerson, J. L., Fossati, S., Ghiso, J. A., Rostagno, A. A., & Rodrigues, C. M. P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8746-x · Cited by 70
Self-citationDecourt, B., D’Souza, G. X., Shi, J., Ritter, A., Suazo, J., & Sabbagh, M. N. (2022) · Aging and disease · doi:10.14336/ad.2021.0529 · Cited by 69
Prevention and Treatment of Alzheimer’s Disease: Biological Mechanisms of Exercise
McGurran, H., Glenn, J. M., Madero, E. N., & Bott, N. T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180958 · Cited by 66
Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease
Beher, D., & Graham, S. L. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1385 · Cited by 66
Lichtlen, P., & Mohajeri, M. H. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05064.x · Cited by 59
“The capability of the liver to uptake, catabolize, and excrete large amounts of Ab, several orders of magnitude above its physiological concentration, may explain not only the very low plasma levels of Ab but also the small fluctuations observed with age and disease status (Ghiso et al. 2004).”
BackgroundInfluentialThe role of β-amyloid peptide in neurodegenerative diseases
Maltsev, A. V., Bystryak, S. M., & Galzitskaya, O. V. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.03.002 · Cited by 72
Sharman, M. J., Morici, M., Hone, E., Berger, T., Taddei, K., Martins, I. J., Lim, W. L. F., Singh, S., Wenk, M. R., Ghiso, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100141 · Cited by 54
Self-citationPCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier
Mazura, A. D., Ohler, A., Storck, S. E., Kurtyka, M., Scharfenberg, F., Weggen, S., Becker-Pauly, C., & Pietrzik, C. U. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04237-x · Cited by 59
Zolezzi, J. M., BastÃas-Candia, S., Santos, M. J., & Inestrosa, N. C. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00176 · Cited by 52
“This situation is most relevant for final Aβ elimination, a process that primarily occurs in the liver (Ghiso et al., 2004; Tamaki et al., 2006; Sagare et al., 2012), and to a lesser extent, in the kidneys (Ghersi-Egea et al., 1996; Sagare et al., 2007; Figure 3).”
BackgroundCritical analysis of Alzheimer rsquo s amyloid-beta nbsp toxicity to mitochondria
Kaminsky, Y. G. (2015) · Frontiers in Bioscience · doi:10.2741/4304 · Cited by 52
Plasma Amyloid-Beta Levels in Patients with Different Types of Cancer
Jin, W., Bu, X., Liu, Y.-H., Shen, L., Zhuang, Z., Jiao, S., Zhu, C., Wang, Q., Zhou, H., Zhang, T., et al. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9682-9 · Cited by 53
“Previous studies indicate that liver plays an important role in peripheral Aβ excretion and catabolism (Ghiso et al. 2004; Tamaki et al. 2006; Hone et al. 2003; Xiang et al. 2015).”
BackgroundVugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 52
Zhao, Y., Qian, R., Zhang, J., Liu, F., Iqbal, K., Dai, C., & Gong, C. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00639-w · Cited by 57
Ullah, R., & Lee, E. J. (2023) · Experimental Neurobiology · doi:10.5607/en23014 · Cited by 57
“In the periphery, several tissues and organs are involved in amyloid-β peptide clearance, including the liver, kidney, and spleen etc. as discuss below [204, 232, 282, 283].”
BackgroundInfluentialEffects of amyloid-beta peptides on hydrogen peroxide-metabolizing enzymes in rat brain in vivo
Kaminsky, Y. G., & Kosenko, E. A. (2008) · Free Radical Research · doi:10.1080/10715760802159057 · Cited by 47
Bridging systemic metabolic dysfunction and Alzheimer’s disease: the liver interface
Song, D., Yang, L., Yang, L.-L., Luo, Y., & Yao, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00849-6 · Cited by 60
Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M. A., Pihlajamäki, J., Soininen, H. S., & Hiltunen, M. O. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 57
Blasko, I., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.006 · Cited by 46
Towards a whole-body systems [multi-organ] lipidomics in Alzheimer’s disease
Astarita, G., & Piomelli, D. (2011) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1016/j.plefa.2011.04.021 · Cited by 44
Endothelin-Converting Enzymes and Related Metalloproteases in Alzheimer's Disease
Pacheco‐Quinto, J., Herdt, A. R., Eckman, C. B., & Eckman, E. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129043 · Cited by 47
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
McIntee, F. L., Giannoni, P., Blais, S., Sommer, G., Neubert, T. A., Rostagno, A., & Ghiso, J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00223 · Cited by 42
“The molecular mass of the synthetic homolog was corroborated bymatrix-assisted laser desorption ionization timeof-flight (MALDI-ToF) mass spectrometry, and its concentration assessed by amino acid analysis, as we previously reported (Ghiso et al., 2004).”
Self-citationMadadi, S., Schwarzenbach, H., Saidijam, M., Mahjub, R., & Soleimani, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0354-3 · Cited by 41
The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels
Abdullah, L. I., Paris, D., Luis, C. A., Quadros, A., Parrish, J., Valdés, L., Keegan, A. P., Mathura, V. S., Crawford, F., & MULLAN, M. J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.058 · Cited by 44
Solito, R., Corti, F., Fossati, S., Mezhericher, E., Donnini, S., Ghiso, J. A., Giachetti, A., Rostagno, A. A., & Ziche, M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.11.002 · Cited by 40
Self-citationKochkina, E. G., Plesneva, S. A., Vasilev, D. S., Zhuravin, I. A., Turner, A. J., & Nalivaeva, N. N. (2015) · Biogerontology · doi:10.1007/s10522-015-9569-9 · Cited by 40
“%) of circulating Ab peptides (Ghiso et al. 2004) the decrease of IDE levels with age will result in a deficit of Ab clearance from the blood.”
BackgroundMonocytes in the Peripheral Clearance of Amyloid-β and Alzheimer’s Disease
Guo, H., Zhao, Z., Zhang, R., Chen, P., Zhang, X., Cheng, F., & Gou, X. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181177 · Cited by 39
Amyloid-β and heart failure in Alzheimer’s disease: the new vistas
Al-Kuraishy, H. M., Sulaiman, G. M., Mohammed, H. A., Mohammed, S. G., Al-Gareeb, A. I., Albuhadily, A. K., Dawood, R. A., Ali, A. A., & Abu-Alghayth, M. H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1494101 · Cited by 48
Ding, Y., Zhong, Y., Baldeshwiler, A., Abner, E. L., Bauer, B., & Hartz, A. M. S. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00245-4 · Cited by 37
Long non-coding RNAs in neurodegenerative diseases
Yang, S., Yang, H., Luo, Y., Deng, X., Zhou, Y., & Hu, B. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105096 · Cited by 34
Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease
Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2023) · FEBS Journal · doi:10.1111/febs.16939 · Cited by 44
Rodríguez‐Casado, A., Alvarez, I., Tolédano, A., de Miguel, E., & Carmona, P. (2007) · Biopolymers · doi:10.1002/bip.20753 · Cited by 35
Pradier, L., Blanchard-Brégeon, V., Bohme, A., Debeir, T., Ménager, J., Benoit, P., Barnéoud, P., Taupin, V., Bertrand, P., Dugay, P., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0447-y · Cited by 38
Gozal, D., Philby, M. F., Alonso-Álvarez, M. L., Téran‐Santos, J., & Gozal, D. (2016) · SLEEP · doi:10.5665/sleep.5838 · Cited by 36
Peripheral amyloid-β clearance mediates cognitive impairment in non-alcoholic fatty liver disease
Peng, X., Zhang, X., Xu, Z., Li, L., Mo, X., Peng, Z., Shan, Z., Yan, H., Xu, J., & Liu, L. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105079 · Cited by 39
García‐Viñuales, S., Sciacca, M. F. M., Lanza, V., Santoro, A. M., Grasso, G., Tundo, G. R., Sbardella, D., Coletta, M., Grasso, G., Rosa, C. L., et al. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2021.105072 · Cited by 35
Katô, M., Kawaguchi, K., Nakai, S., Murakami, K., Hori, H., Ohashi, A., Hiki, Y., Ito, S., Shimano, Y., Suzuki, N., et al. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0844-5 · Cited by 34
“Abs were thought to be degraded mainly in the liver (Ghiso et al. 2004).”
Metabolite Clearance During Wakefulness and Sleep
Hladky, S. B., & Barrand, M. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_37 · Cited by 39
“Clearance of Aβ from blood plasma is rapid with a half-life of a few minutes, primarily by metabolism in the liver and spleen (Ghiso et al. 2004; Kandimalla et al. 2005).”
Meeker, K. D., Meabon, J. S., & Cook, D. G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142304 · Cited by 35
The role of lipoprotein receptors on the physiological function of APP
Wagner, T., & Pietrzik, C. U. (2011) · Experimental Brain Research · doi:10.1007/s00221-011-2876-8 · Cited by 32
Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies
Yang, H., Li, J., Li, X., Ma, L., Hou, M., Zhou, H., & Zhou, R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.927530 · Cited by 34
Near-infrared target enhanced peripheral clearance of amyloid-β in Alzheimer's disease model
Ma, M., Liu, Z., Gao, N., Dong, K., Pi, Z., Kang, L., Du, X., Ren, J., & Qu, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121065 · Cited by 29
Antibodies to Potato Virus Y Bind the Amyloid β Peptide
Friedland, R. P., Tedesco, J. M., Wilson, A. C., Atwood, C., Smith, M. A., Perry, G. L., & Zagorski, M. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802088200 · Cited by 28
Mohamed, L. A., & Kaddoumi, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052514 · Cited by 32
“Several studies have demonstrated the involvement of liver as a main pathway in the clearance of Ab from the peripheral circulation and have shown that faulty clearance of plasma-free Ab contributes largely to AD (Ghiso et al., 2004; Sagare et al., 2007; Sutcliffe et al., 2011).”
BackgroundGlobal cPILOT analysis of the APP/PS‐1 mouse liver proteome
Evans, A. R., Gu, L., Guerrero, R., & Robinson, R. A. S. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400149 · Cited by 27
Yeh, C.-W., Liu, H., Lin, L.-C., Liou, K.-T., Huang, Y., Lin, C., Tzeng, T.-T., Shie, F., Tsay, H.-J., & Shiao, Y. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.07.036 · Cited by 31
Lai, P.-H., Wang, T.-H., Zhang, N.-Y., Wu, K.-C., Yao, C. J., & Lin, C. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02086-2 · Cited by 29
Garcia, J., Chang, R., Steinberg, R. A., Arce, A., Yang, J., Eb, P. V. D., Abdullah, T., Chandrashekar, D. V., Eck, S. M., Meza, P., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.930402 · Cited by 27
“This may be true regarding Aβ homeostasis, where the liver is involved in Aβ clearance from blood and peripheral organs (Ghiso et al., 2004; Tamaki et al., 2006; Wang et al., 2017; Bassendine et al., 2020), but is also a potential source for Aβ in the periphery and blood, which can ultimately accumulate in the brain (…”
BackgroundHeart and Brain: Complex Relationships for Left Ventricular Dysfunction
Daniele, G., DiLucia, S., Masci, P. G., & del Monte, F. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01318-w · Cited by 28
Metadata
- Authors
- Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B.
- Affiliations
- New York University (US)
- Instituto de Salud Carlos III (ES)
- Corresponding author
- Ghiso, Jorge
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 279
- Issue
- 44
- Pages
- 45897-45908
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2062647232
- Cited by
- 209
- References
- 68
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 18 · 2023: 5 · 2022: 9 · 2021: 19 · 2020: 15 · 2019: 8 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 8 · 2014: 8 · 2013: 11 · 2012: 11
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5832 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P01AG010491, AG10491, R01AG008721, AG-08721, AG05891)
- National Institute of Neurological Disorders and Stroke (NS 38777, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- amyloid-beta, Aβ40, amyloid-beta 42, plasma clearance, hepatic uptake, biliary excretion, hepatocytes, peptide oligomerization, peptide conformation, beta-sheet, endocytosis, HepG2 cells, Alzheimer's disease
- MeSH terms
- Amino Acid Sequence, Animals, Bile, Humans, Iodine Radioisotopes, Liver, Male, Molecular Sequence Data, Tissue Distribution, Amyloid beta-Peptides, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.